<unk>  is used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban. There are no randomised clinical trials as of 2019. Studies in healthy volunteers show that the molecule binds factor Xa inhibitors and counters their anti-Xa-activity. The only published clinical trial is a prospective, open label, single group study. This study reports results on 352 people and demonstrates a reduction of anti-Xa-activity while also showing an excellent or good hemostatic efficacy in 82%. While people who were expected to die in 30 days were excluded from the study, 14% of participants died. There was no relationship between hemostatic efficacy and reduced anti-Xa-activity. The FDA has demanded a randomised clinical trial: the first results are not expected before 2023.
Andexanet alfa
Vonicog alfa
Efgartigimod alfa
Crofelemer
Damoctocog alfa pegol
Bulevirtide
Fludroxycortide
Clinatec